

ZESTAGEN SA, A CANCER MONOCLONAL ANTIBODY COMPANY

Zestagen S.A. is a Swiss biotechnology company developing a monoclonal antibody for cancer. Zestagen owns intellectual property discovered at the Hellenic Pasteur Institute in Athens. Zestagen's current founding shareholders are Ventac Partners, an international business development corporation, and Postel Investments Ltd.

Zestagen is seeking 3.0 M CHF in series A capital to take the lead antibody through to clinical Phase I within 27 months from funding. Capital injection can be split in three tranches. A 1st tranche of 0.5 M CHF will be used to select the preclinical candidate. A 2nd tranche of 1.3 M CHF will be used for GLP efficacy and GMP studies. A 3rd tranche of 1.2 M will bring the candidate through IND-enabling, GLP safety & toxicology studies.

ZESTAGEN AT A GLANCE

Swiss VC Board-recommended #1 biotech startup to invest
(of 7 biotechs out of 50 tech start ups; Bilan magazine, Feb 13)



THERAPEUTIC TARGET

- Extracellular Heat Shock Protein-90 (ehsp90)
- ehsp90 is expressed at the surface of cancer cells but not of normal adult cells
- Preliminary data establish ehsp90 as a metastasis-promoting agent

ANTIBODIES

- Light chain antibodies
- Selective binding to ehsp90; no Ab internalization and hence low predicted toxicity against intracellular hsp90
- Potent anti-tumor activity in vivo (breast cancer & melanoma animal models)
- 27 months to enter Phase I

INTELLECTUAL PROPERTY

- Patent portfolio matured to PCT - protection extending to 2030-31
- Patent search and analysis positive

PEOPLE

- International team with strong experience in cancer drug development

MANAGEMENT

Dr. Nassos Alevizopoulos, CEO
+41-21-652-8849

nalevizo@zestagen.com

Zestagen SA
4, rue de la Corniche
1066, Epalinges (Lausanne)
Switzerland
www.zestagen.com

Martin Austin, Chairman
+41-61-283-4460

mcaustin@ventac-partners.com